(
A) Peptide bond absorbance traces (A
230 nm) of purified BiP (50 µM) lacking its C-terminal ‘lid’ (∆554–654) without (lidless) or with a compounding ADDA mutation (ADDA-lidless) following fractionation by size-exclusion chromatography (SEC-3 column). The distinct peaks I, II and III (described in the legend to
Figure 2) are indicated. (
B) Trace as in ‘A’ of lidless BiP incubated with or without ATP (5 mM) before fractionation. Note the dissociation of oligomers upon exposure to ATP. (
C) Peptide bond absorbance trace (A
230 nm, black) and lucifer yellow (LY) fluorescence trace (Ex: 430 nm, Em: 525 nm; red) of purified lidless BiP (50 µM; as in ‘A’) supplemented with tracer concentrations of LY-labeled BiP-binding peptide (1 µM; as in
Figure 2E) and fractionated as in ‘A’. The peak corresponding to the free peptide is indicated. Note the disproportionately diminished engagement of peptide by the larger lidless BiP oligomers, (
D) Peptide bond absorbance trace of purified ADDA-lidless mutant BiP (50 µM) (A
230 nm, black) and fluorescence trace (red) of tracer concentrations (1 µM) of fluorescent LY-labeled V461F mutant BiP (V461F-LY) fractionated by size-exclusion chromatography either before (-SubA) or after (+SubA) cleavage with SubA (36 ng/µl; as in
Figure 3B). Peaks I, II and III are marked as is the new fluorescent peak emanating from the V461F-LY cleavage product (CP). Note that fluorescent peak I is attenuated upon treatment with SubA, whereas peak II is resistant. The peptide-bond absorbance trace, contributed largely by the ADDA mutant lidless BiP, is unchanged by SubA cleavage.